Richard Law
Stock Analyst at Goldman Sachs
(3.30)
# 1,050
Out of 5,090 analysts
70
Total ratings
39.39%
Success rate
25.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $18 → $26 | $27.21 | -4.45% | 6 | Nov 21, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $109.60 | +23.18% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $31.20 | -7.05% | 2 | Oct 30, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Neutral | $35 → $40 | $46.67 | -14.29% | 1 | Sep 26, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $38.50 | +35.06% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $32.02 | -6.31% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $14.90 | +450.34% | 4 | Aug 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $6.96 | -56.90% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.32 | +291.57% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $29.45 | +5.26% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $38.55 | -22.18% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $73 | $96.14 | -24.07% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $17.41 | -36.82% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $27.09 | +73.50% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $56.88 | +10.76% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $66.62 | -44.46% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $9.61 | +690.84% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.42 | +478.51% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $12.79 | +376.94% | 4 | May 8, 2023 |
Olema Pharmaceuticals
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $26
Current: $27.21
Upside: -4.45%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $109.60
Upside: +23.18%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $31.20
Upside: -7.05%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $46.67
Upside: -14.29%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $38.50
Upside: +35.06%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $32.02
Upside: -6.31%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $14.90
Upside: +450.34%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $6.96
Upside: -56.90%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.32
Upside: +291.57%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $29.45
Upside: +5.26%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $38.55
Upside: -22.18%
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $96.14
Upside: -24.07%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $17.41
Upside: -36.82%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $27.09
Upside: +73.50%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $56.88
Upside: +10.76%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $66.62
Upside: -44.46%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $9.61
Upside: +690.84%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.42
Upside: +478.51%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $12.79
Upside: +376.94%